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Abstract
 
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF, VEGF-A) is a
multifunctional cytokine with important roles in pathological angiogenesis. Using an adeno-
viral vector engineered to express murine VEGF-A
 
164
 
, we previously investigated the steps and
mechanisms by which this cytokine induced the formation of new blood vessels in adult immu-
nodeficient mice and demonstrated that the newly formed blood vessels closely resembled those
found in VEGF-A–expressing tumors. We now report that, in addition to inducing angiogen-
esis, VEGF-A
 
164
 
 also induces a strong lymphangiogenic response. This finding was unantici-
pated because lymphangiogenesis has been thought to be mediated by other members of the
VPF/VEGF family, namely, VEGF-C and VEGF-D. The new “giant” lymphatics generated
by VEGF-A
 
164
 
 were structurally and functionally abnormal: greatly enlarged with incompetent
valves, sluggish flow, and delayed lymph clearance. They closely resembled the large lymphat-
ics found in lymphangiomas/lymphatic malformations, perhaps implicating VEGF-A in the
pathogenesis of these lesions. Whereas the angiogenic response was maintained only as long as
VEGF-A was expressed, giant lymphatics, once formed, became VEGF-A independent and
persisted indefinitely, long after VEGF-A expression ceased. These findings raise the possibility
that similar, abnormal lymphatics develop in other pathologies in which VEGF-A is overex-
pressed, e.g., malignant tumors and chronic inflammation.
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Introduction
 
Most mammalian tissues are supplied by two interconnected
but largely independent vascular systems, the one carrying
blood and the other lymph. Much has been learned in re-
cent years about the generation of the blood vasculature
and the two distinct but overlapping processes that are re-
sponsible: vasculogenesis (de novo generation of blood
vessels from primitive precursor cells as occurs in develop-
ment) and angiogenesis (generation of new blood vessels
from preexisting blood vessels; references 1–4). Vascu-
lar permeability factor/vascular endothelial growth factor
(VPF/VEGF, VEGF-A)
 
*
 
 is a multifunctional cytokine that
has essential roles in both processes (5–8). It mediates its
several activities primarily through interaction with two re-
ceptor tyrosine kinases, VEGF receptor (VEGFR)-1 and
VEGFR-2, that are selectively, though not exclusively, ex-
pressed on vascular endothelium. Another member of the
VPF/VEGF family, placenta growth factor (PlGF), also has
a role in pathological angiogenesis, interacting with
VEGFR-1 but not VEGFR-2 (9).
Less is known about the cytokines responsible for gener-
ating the lymphatic vascular system. Recent work from
several laboratories has identified critical roles for two
members of the VPF/VEGF cytokine family, VEGF-C and
VEGF-D (10–16). Mutation or loss of these cytokines or
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their receptor (VEGFR-3) leads to impaired lymphatic de-
velopment and human disease whereas overexpression of
VEGF-C or VEGF-D induces increased lymphangiogene-
sis in animal systems. Both VEGF-C and VEGF-D induce
angiogenesis as well as lymphangiogenesis under appropri-
ate circumstances (10, 15, 16) but VEGF-A is thought not
to induce lymphangiogenesis (14, 17–19).
When murine VEGF-A
 
164
 
 was introduced into adult
mouse tissues by means of an adenoviral vector, angiogene-
sis developed according to a characteristic series of steps
(20, 21). Within a matter of hours, infected host cells ex-
pressed VEGF-A
 
164
 
, inducing microvascular hyperperme-
ability, extravasation of plasma and plasma proteins, deposi-
tion of extravascular fibrin gel and edema. Within the same
time frame, preexisting capillaries and venules enlarged
greatly to form thin-walled, hyperpermeable, pericyte-poor
“mother” vessels; over the course of the next 2 wk, mother
vessels evolved along several independent lines to form
daughter capillaries, glomeruloid bodies, and arterio-
venous malformations. Subsequently, as VEGF-A expres-
sion waned, the angiogenic response resolved with a return
to near normal microvascular density by 
 
 
 
8 wk.
We here report the unanticipated finding that, in addi-
tion to angiogenesis, VEGF-A also induces proliferation of
lymphatic endothelium, resulting in the formation of
greatly enlarged and poorly functioning lymphatic chan-
nels. Unlike angiogenesis, the lymphangiogenic response
became VEGF-A independent, as, once formed, the newly
formed “giant” lymphatics persisted indefinitely, long after
VEGF-A expression and tissue edema had ceased. These
findings raise the possibility that abnormal lymphangiogen-
esis may also be expected in other circumstances that are
characterized by VEGF-A overexpression such as chronic
inflammation and malignant tumors (5).
 
Materials and Methods
 
Adenoviral Vectors and Animals.
 
A nonreplicating adenoviral
vector was engineered to express the predominant (164 amino
acid) murine isoform of VEGF-A as described previously (20).
An adenoviral vector expressing placenta growth factor (murine
PlGF-2) was provided by Dr. Peter Carmeliet, Leuven, Belgium.
Vectors were grown to titers of 
 
 
 
10
 
12
 
 PFU/ml and purified us-
ing a double cesium chloride banding procedure by Qbiogene.
Immediately before use, vectors were desalted using Quick Spin,
High Capacity G-50 Sephadex columns (Boehringer) and diluted
in PBS–3% glycerol. 5 
 
 
 
l of vectors containing 0.5–1.0 
 
 
 
 10
 
8
 
PFU were injected into the ears of 4–6-wk-old female athymic
Nu/Nu mice (National Cancer Institute, Bethesda, MD) as de-
scribed previously (20, 21). More than 200 mice participated in
this study. Animal protocols were approved by the BIDMC Insti-
tutional Animal Care and Use Committee.
 
Microscopic Studies.
 
Mice were killed by CO
 
2
 
 narcosis. For
preparation of Giemsa-stained 1 
 
 
 
m Epon sections and for elec-
tron microscopy, ears were fixed in paraformaldehyde-glutaralde-
hyde and processed as described previously (20, 21). For quanti-
fying lymphatic endothelial cell proliferation, mice were
anesthetized with Avertin (200 mg/kg tribromoethanol IP) and
injected intravenously with 50 
 
 
 
Ci of [
 
3
 
H]thymidine. 1 h later,
mice were killed and ears were fixed and processed for autora-
diography on 1 
 
 
 
m Giemsa-stained Epon sections (22).
Rabbit antibodies to the extracellular soluble domain of mu-
rine VEGFR-2 (flk-1) were the kind gift of Drs. Rolf Brekken
and Philip Thorpe, University of Texas Southwestern, Dallas,
TX (23). For immunohistochemical staining, mouse ears were
immersed in freshly prepared 4% paraformaldehyde in 0.02 M
phosphate buffer, pH 7.4. After 4 h at room temperature, tissues
were transferred to 30% sucrose in PBS, pH 7.4, and incubated
overnight at 4
 
 
 
C before embedding in OCT compound (Miles
Diagnostics). Frozen 5–10 
 
 
 
m cryostat sections were collected on
microscopic slides for immunostaining (23).
For immunofluorescence, 6-
 
 
 
m frozen sections were fixed in
ice-cold acetone and 80% methanol, rehydrated in PBS, and
double stained with a primary rabbit antibody to the murine hy-
aluronan receptor LYVE-1 (provided by Dr. D. Jackson, Institute
of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
[24]) and with a rat monoclonal antibody to mouse CD31 (BD
Biosciences). Corresponding secondary anti–rabbit IgG or anti–
rat IgG antibodies were labeled with Alexa Fluor 488 or 594, re-
spectively (Molecular Probes). Sections were examined in a Ni-
kon E-600 fluorescent microscope.
For in situ hybridization, tissues were fixed and frozen in OCT
compound as for immunohistochemistry but with RNase free re-
agents. Cryostat sections were hybridized with antisense and
sense (control), single stranded, 
 
35
 
S-labeled RNA probes to mu-
rine VEGF-A, VEGF-C, VEGF-D, PlGF, VEGFR-1, and
VEGFR-2 as described previously (25).
 
Intravital Perfusion of Lymphatics.
 
These experiments were slightly
modified after Hudack and McMaster (26). Mice were anesthe-
tized with sodium pentobarbital (75 mg/kg) and cradled in a
transparent acrylic resin mold (Syndicate Sales, Inc.). Ears were
mounted flat on the resin support and held in place by silicone
vacuum grease and viewed in a Wild M400 Photomacroscope.
Colloidal carbon (Higgins nonwaterproof drawing ink; Sanford)
was diluted 1:1 in Tyrode’s buffer and injected through a 10-
 
 
 
m
prepulled borosilicate glass micropipette attached to a 500-
 
 
 
l
Hamilton syringe. The micropipette was repeatedly injected into
the dorsal surface of the peripheral ear until a lymphatic capillary
was entered. Additional carbon (5–20 
 
 
 
l) was then slowly in-
jected under the control of a threaded plunger to avoid overfilling
and vessel damage. For photography, ears were flooded with im-
mersion oil, coverslipped, and photographed with a SPOT In-
sight Digital camera.
 
Confocal Scanning Fluorescence Microscopy.
 
For simultaneous vi-
sualization of blood and lymphatic vessels, mice were anesthe-
tized as above and injected intravenously with 2 
 
 
 
 10
 
6
 
 MW
lysine-fixable fluorescein isothiocyanate-labeled dextran (FITC-
dextran, 6 mg in 0.2 ml saline; Molecular Probes). Immediately
thereafter, peripheral ear lymphatics were injected with 2 
 
 
 
 10
 
6
 
MW tetramethyl-rhodamine–dextran (TMR-dextran, 30 mg/ml
in saline; Molecular Probes) as for colloidal carbon. 30 min later,
ears were fixed in 4% formaldehyde in PBS for 4 h, washed in
PBS-2% sucrose, mounted with Vectashield (Vector Laborato-
ries) in imaging chambers (Sigma-Aldrich), and visualized with a
1024 MRC Bio-RAD confocal microscope equipped with a
Krypton Argon laser. Five to seven fields from the same region of
each ear were visualized. Data were collected with confocal set-
ting in the sequential mode, exciting and collecting one channel
(fluorophore) at a time to allow optimal separation of green and
red fluorescence. Stacks of optical sections were collected by op-
tical z sectioning (z step 
 
 
 
 4 
 
 
 
m). Individual optical sections or
vertical projections were processed using the Bio-Rad Laborato- 
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Figure 1. Lymphangiogenic response induced by Ad-VEGF-A164 in nude mouse ears. (a) Normal lymphatic in control ear skin (arrow indicates a
valve). (b) Lymphatics at 3 d after Ad-VEGF-A164 are distended from dermal edema but have already enlarged further as the result of endothelial cell di-
vision and are transitioning into giant lymphatics. (c–h) Giant lymphatics occupy large portions of the dermis at 7–131 d after Ad-VEGF-A164. Panel c
illustrates giant lymphatics that contain colloidal carbon injected as described in Materials and Methods and illustrated macroscopically in Fig. 5. Lym-
phatic (L) in g contains fibrin clot whereas three unlabeled lymphatics (top right) are filled with colloidal carbon. (i and j) Giant lymphatics wrap around
glomeruloid bodies (GB) 13 d after Ad-VEGF-A164. (k) Autoradiograph showing [3H]thymidine incorporation by lymphatic endothelial cells (arrows) at
10 d after Ad-VEGF-A164. L, lymphatics. Giemsa stained 1  m Epon sections. Bars: a–h, 100  m; i and j, 50  m; k, 25  m. 
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ries LaserSharp Software version 3.2 and saved as TIFF files in
Adobe Photoshop 6.0.
 
Results
 
Lymphangiogenic Response to Ad-VEGF-A
 
164
 
.
 
Lym-
phatic capillaries are normally collapsed and their initial re-
 
sponse (1–3 d) to VEGF-A
 
164
 
 was, as expected, that of ho-
meostatic distension (Fig. 1, a and b). VEGF-A
 
164
 
 is a
potent vascular permeabilizing factor that induces extrava-
sation of blood plasma and consequent tissue edema (5, 7).
In response to interstitial fluid accumulation, lymphatics
distend in response to tension applied to the anchoring fila-
ments connecting them to the surrounding connective tis-
sues (27, 28).
Incorporation of [
 
3
 
H]thymidine was not observed in
lymphatic capillary endothelial cells of normal mouse ears
or of ears injected 1 d prior with Ad-VEGF-A
 
164 
 
(Fig. 2).
Low level labeling was first detected on day 2, and, thereaf-
ter, lymphatic capillary endothelium incorporated increas-
ing amounts of thymidine until by 8 d nearly 25% of cells
were labeled (Figs. 1 k and 2). In parallel with lymphatic
endothelial cell proliferation, lymphatic capillaries enlarged
progressively and, by 2–3 wk had attained cross-sectional
areas many times larger than the homeostatic response
to tissue edema (Fig. 1, c–e). These “giant” lymphatics
formed a meshwork of large, irregularly shaped vessels that
occupied substantial portions of the dermis and persisted
indefinitely, wrapping around blood vascular structures
such as glomeruloid bodies (Fig. 1, f–j). After 8 d, the label-
ing index decreased steadily but as late as 3 wk nearly 1%
of lymphatic endothelial cells continued to incorporate
[
 
3
 
H]thymidine (Fig. 2).
The lymphatic endothelium lining giant lymphatics
stained strongly and consistently with antibodies to
VEGFR-2 (23, 29) and to LYVE-1 (24), not differing in
this respect from normal lymphatics (Fig. 3). In accord with
earlier work (20), infected host cells expressed VEGF-A
 
164
Figure 2. Percent of lymphatic endothelial cells labeled by [3H]thymi-
dine (mean   std error) at intervals after ear injection with Ad-VEGF-A164
or Ad-PlGF. Values at successive times (based on 3–6 animals per time
point) were compared with those at time zero using Dunn’s multiple
comparisons test. *P   0.05; **P   0.01.
Figure 3. Immunostaining of
lymphatics for VEGFR-2 (a–e) and
for the hyaluronan receptor LYVE-1
(f and g). Immunoperoxidase stain-
ing of control lymphatics (a and b)
or giant lymphatics (c–e) at indicated
times after Ad-VEGF-A164. Note
bridging of lymphatics by VEGFR-2–
positive endothelium (d, arrows). L,
lymphatics; v, micro blood vessels
whose endothelial cells also stain. (f
and g) Immunofluorescence stain-
ing of lymphatics with anti-LYVE
antibody (green) and micro-blood
vessels with CD31 (red), 6 and 14 d
after Ad-VEGF-A164. Bars: a, b, and
e, 10  m; c and d, 20  m; f and g,
200  m. 
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mRNA steadily for 
 
 
 
2 wk as determined by in situ hy-
bridization, after which expression progressively declined
and became undetectable by 
 
 
 
4 wk (20, 21). mRNAs en-
coding both VEGFR-1 and VEGFR-2 were similarly
overexpressed in the endothelium of newly formed blood
vessels (reference 20, and unpublished data). We did not
detect expression of either VEGF-C or VEGF-D mRNA
at any time point. Ears injected with Ad-PlGF developed a
characteristic angiogenic response (9) but neither edema
nor lymphangiogenesis (Fig. 2).
 
Function of Giant Lymphatics.
 
An important function of
lymphatics is to take up and return to the blood extravasated
plasma and plasma proteins in excess of that reabsorbed by
capillaries. To determine whether giant lymphatics were
able to take up macromolecules that had extravasated from
leaky blood vessels, we injected tracer FITC-dextran (green)
intravenously into mice that had had one ear injected 4 d
previously with Ad-VEGF-A
 
164
 
, leaving the other ear unin-
jected. Giant lymphatics were labeled by injecting macro-
molecular TMR-dextran (red) directly into small lymphatics
peripheral to the zone of VEGF-A
 
164
 
-induced edema, an-
giogenesis, and lymphangiogenesis. As expected, FITC-
dextran was almost completely retained within the blood
vessels of control ears and therefore was not available in the
interstitium for uptake by lymphatics (Fig. 4, a–c). By con-
trast, FITC-dextran leaked extensively from microvessels
rendered hyperpermeable by Ad-VEGF
 
164
 
 and was taken up
by giant lymphatics (Fig. 4, d–g). Some giant lymphatics ex-
hibited zones of incomplete filling as the result of segmental
intraluminal clotting and thrombosis (see below); such zones
of interrupted filling were often traversed by narrow open
channels that allowed passage of tracer (Fig. 4, d–g).
The function of the Ad-VEGF-A
 
164
 
-induced giant lym-
phatics was further tested by assessing tracer flow and clear-
ance. For these studies, colloidal carbon was injected into
the peripheral lymphatics as above for TMR-dextran. In
normal control ears, carbon entered fine, distinct, lymphat-
ics that extended radially from the periphery to the base of
the ear; these were punctuated by periodic bulbous swell-
ings that marked valves (Fig. 5 a). Though joined at inter-
vals by interconnecting side branches, there was minimal
sideways filling. Therefore, multiple injection sites were re-
quired to fill the majority of lymphatics in normal ears (Fig.
5 a). Carbon injected at individual sites remained largely
within one or two radially oriented lymphatics and drained
rapidly and completely into postauricular and cervical
lymph nodes within 20 min (Fig. 5, m and n). Similar re-
sults were obtained in mice whose ears had been injected
with Ad-PlGF (Fig. 5, b–d), a finding consistent with the
minimal proliferation of lymphatic endothelium induced
by PlGF (Fig. 2).
Very different results were obtained when colloidal car-
bon was injected into the terminal ear lymphatics of mice
previously injected with Ad-VEGF-A
 
164
 
 (Fig. 5, e–h). In
such mice, both radial and interconnecting lymphatics en-
larged greatly to form giant lymphatics and no longer ex-
hibited the bulbous swellings that marked the location of
valves in normal lymphatics. As the result of cross-sectional
enlargement, the valves in giant lymphatics were unable to
close to prevent backward and sideways flow. Upon enter-
ing giant lymphatics, therefore, carbon from a single injec-
tion site was diverted into interconnecting side channels
and, within a few minutes, filled lymphatics spread over a
large portion of the ear surface (Fig. 5, i–l). However,
Figure 4. Confocal microscopy of
lymphatic and microvascular plex-
uses in ears of a control mouse (a–c)
and a mouse injected 4 d previously
with Ad-VEGF-A164 (d–g). FITC-
dextran (green) was injected intrave-
nously into the tail vein and TMR-
dextran (red) was microinjected into
the peripheral ear lymphatics. (a)
Normal ear lymphatic plexus delin-
eated by TMR-dextran. (b) Normal
ear blood microvasculature delin-
eated by FITC-dextran. (c) Com-
posite retains distinct green and red
compartments for the most part, in-
dicating little or no lymphatic uptake
of FITC-dextran. (d and e) TMR-
dextran, reproduced in both black
and white and in red, within a giant
lymphatic. Centrally the channel is
partially obstructed (presumably by
fibrin clot, see text and Figs. 6 and
7), such that the upper and lower
portions are connected only through
narrow channels that allow tracer
flow (best illustrated in d). (f) FITC-
dextran fills leaky micro-blood ves-
sels and has entered the lymphatic illustrated in d and e. (g) Merged image. Yellow color indicates FITC-dextran extravasated from leaky blood vessels has
been taken up by the giant lymphatic infused with TMR-dextran. Bars, 50  M. 
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lymph flow in giant lymphatics was sluggish and clearance
of colloidal carbon was greatly delayed; substantial amounts
of tracer persisted within giant lymphatics for long periods of
time after cessation of tracer injection (Fig. 5, o and p), of-
ten for more than 24 h. Giant lymphatics with these prop-
erties were evident as early as 3 d in ears injected with Ad-
VEGF-A
 
164
 
 and persisted indefinitely (Fig. 5, e–h). That
the carbon injected was actually present in and confined to
giant lymphatics is illustrated in Fig. 1, c and g.
 
Intravascular Clotting and Remodeling of Giant Lymphatics.
 
Whereas many giant lymphatics persisted as large, patent
structures, others underwent intravascular clotting with
consequent partial or complete obstruction to flow by fi-
brin clot (Figs. 6 and 7). Although occasional red blood
cells leaked from blood vessels and entered lymphatics (Fig.
6, d–f, and h), platelets were not recognized by either light
or electron microscopy. Lymphatic endothelial cells, iden-
tified by their staining for VEGFR-2 (Fig. 3) and by ultra-
structural features (Fig. 7), used fibrin as a substrate for in-
traluminal migration, forming a fishnet-like meshwork of
interconnecting cells that bridged the lymphatic lumens
and divided them into a multiplicity of smaller channels
(Figs. 6 and 7). Fibrin bridges were subsequently replaced
by thin bundles of collagen.
 
Discussion
 
The data presented here indicate that murine VEGF-
A
 
164
 
 induces lymphangiogenesis in addition to angiogene-
sis. This finding was unanticipated in that lymphangiogene-
sis has been thought to be the purview of two other
members of the VPF/VEGF family, VEGF-C and VEGF-D,
neither of which was detectably expressed in these ex-
periments. The initial response of lymphatic capillaries
to VEGF-A
 
164
 
 was distension, attributable to interstitial
edema; this was followed by proliferation of lymphatic en-
dothelium, leading to gross enlargement and the formation
of “giant” lymphatics that exhibited sluggish flow and de-
layed tracer clearance. The angiogenic response induced by
VEGF-A
 
164
 
 continued only as long as VEGF-A
 
164
 
 was ex-
pressed and completely resolved by 
 
 
 
2 mo. On the other
hand, giant lymphatics persisted indefinitely, for at least a
year, long after VEGF-A
 
164
 
 expression had ceased and
edema had resolved. Thus, whereas VEGF-A is a well
Figure 5. Ear lymphatics after in-
travital infusion of colloidal carbon
in a control mouse and in mice in-
jected at indicated intervals with
Ad-PlGF or Ad-VEGF-A164. (a)
Control ear. Multiple injection sites
(black blotches at top) were required
to fill the lymphatic network. Note
periodic bulbous swellings that iden-
tify valves. (b–d) Lymphatic filling in
ears of mice injected at indicated
times with Ad-PlGF. Injecting mi-
cropipette is shown in place in b.
Lymphatics retain bulbous valve
markings. (e–h) Pattern of lymphatic
filling in ears of mice injected previ-
ously, as indicated, with Ad-VEGF-
A164. Giant lymphatics are apparent
as early as 3 d (e) and persist through
day 270. Bulbous valve markings are
lost. (i–l) Kinetics of lymphatic fill-
ing in ear of a mouse 84 d after in-
jection with Ad-VEGF-A164. Note
widespread filling of lymphatic net-
work by 4 min from a single injec-
tion site (that with the micropipette
in place). An earlier injection site (to
left of pipette) failed to engage the
terminal lymphatics. (m–p) Clear-
ance of carbon from control ear
lymphatics (m and n) is complete by
20 min but at 35 d after Ad-VEGF-
A164 ear lymphatics still retain abun-
dant tracer after 150 min (o and p). 
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known survival factor for newly formed blood vessels, it is
apparently not required for the sustenance of newly formed
giant lymphatics. Giant lymphatics also formed in perito-
neal lining tissues in response to VEGF-A
 
164
 
 (unpublished
data); therefore the lymphangiogenic response was not
unique to ear skin. In contrast to Ad-VEGF-A
 
164
 
, an ade-
noviral vector expressing murine PlGF induced angiogene-
sis (9) but not lymphangiogenesis.
There are similarities and differences in the steps and
mechanisms by which VEGF-A
 
164
 
 induced the formation
Figure 6. Intraluminal fibrin clot formation and transluminal bridging of giant lymphatics at indicated times after Ad-VEGF-A164 injection. None of
the lymphatics illustrated had been injected with carbon or other agents. (a and b) Fibrin clot (*) within giant lymphatics at 10–11 d; note transluminal
bridging by lymphatic endothelium. (c–i) Migrating lymphatic endothelial cells formed transluminal bridges across giant lymphatics, dividing their lumens
into multiple smaller, endothelium-lined channels. Initially fibrin formed a substrate for endothelial cell migration but was subsequently digested and re-
placed by collagen. By 22 d (i) bridges had become quite cellular. Note red blood cells within lymphatics (d–f, h). L, giant lymphatics. Giemsa stained 1
 m Epon sections. Bars: a, b, and d–i, 50  m; c, 25  m. 
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of mother blood vessels and giant lymphatics. Mother
blood vessels formed as the result of two temporally distinct
processes (20): (a) degradation of venule endothelial cell
basement membranes, detachment of pericytes, and transfer
of stored intraendothelial cell membrane to the plasma
membrane; together these events allowed vessel enlarge-
ment within 18 h, entirely independent of cell division. (b)
Proliferation of vascular endothelial cells and pericytes, be-
ginning on day 2 and reaching a peak on days 7–8.
Giant lymphatics also formed in two steps but these
overlapped temporally. The second step in giant lymphatic
formation, proliferation of lymphatic endothelial cells, par-
alleled the proliferation of vascular endothelial cells in en-
larging mother blood vessels and followed nearly identical
kinetics (illustrated for lymphatics in Fig. 2). However, the
first step in the development of giant lymphatics was dis-
tinctly different from that leading to the formation of
mother blood vessels. Unlike venules, lymphatic capillaries
for the most part lack pericytes, have poorly developed
basement membranes, and are flattened cells with limited
internal membrane stores (28, 30); therefore, changes in
these elements, characteristic of the first stage of mother
blood vessel formation, had no role in initiating lymphatic
enlargement. Instead, lymphatics, which are collapsed in
normal tissues, became distended by 1 d in response to
VEGF-A
 
164
 
-induced microvascular hyperpermeability, tis-
sue edema, and the consequent outward pull of anchoring
filaments (27, 28). Apart from this homeostatic distension,
lymphatics did not increase in size until their lining endo-
thelium began to proliferate (Figs. 1 and 2).
VEGF-A
 
164
 
–induced giant lymphatics were functional
in that they took up macromolecules extravasated from
hyperpermeable microvessels and transported them to
draining lymph nodes (Fig. 4). However, flow in giant
lymphatics was sluggish and tracer clearance was markedly
delayed (Fig. 5), as compared with normal lymphatics, for
at least two reasons. First, the valves of giant lymphatics
were unable to close properly and were thus unable to pre-
vent lateral lymph flow into side channels. Flow in giant
lymphatics was also impeded by intralymphatic clotting
and thrombosis (Figs. 6 and 7). Fibrinogen, like other
plasma proteins, extravasated in response to VEGF-A–
induced changes in venular permeability, and substantial
amounts clotted in the extravascular space (20). However,
extravasated fibrinogen was also taken up by giant lym-
phatics and underwent intraluminal clotting, forming a par-
tial or in some cases a complete barrier to lymphatic flow
(Figs. 6 and 7). The precise mechanisms responsible for trig-
gering intralymphatic clotting are not known. Platelets were
not observed within giant lymphatics by light or electron
microscopy. However, clotting was favored by the high in-
traluminal concentration of fibrinogen and sluggish flow.
Fibrin deposited within giant lymphatics provided a sub-
strate for intraluminal migration of lymphatic endothelial
cells. These cells remodeled the fibrin clot, replacing it over
time with a fishnet-like meshwork of cellular bridges that
divided the original large lumens into multiple smaller
channels (Figs. 6 and 7). This process has a parallel in the
evolution of mother blood vessels that are induced by Ad-
VEGF-A
 
164
 
 and also in VEGF-A–expressing tumors; in
both cases endothelial cells lining blood vessels and giant
lymphatics extended into and across the lumen, forming
bridges that divided larger structures into smaller channels
of capillary size (20, 22). It also has a parallel in the well-
known recanalization of thrombosed blood vessels.
Several recent papers (14, 18, 19) have reported that hu-
man Ad-VEGF-A
 
165
 
 induces angiogenesis but not lym-
phangiogenesis in rodents, though one of these (19) did re-
port lymphatic dilatation. In part these negative findings
may reflect the selection of limited or nonoptimal time
points (19); in one report, lymphangiogenesis may have
been obscured by the use of immunocompetent animals
that developed a strong inflammatory response against the
adenoviral vector (18). Use of human rather than murine
Figure 7. Electron micrographs of giant lymphatics at 21 d (a) and 14 d (b) after Ad-VEGF-A164 injection, illustrating intraluminal fibrin deposits and
transluminal bridging by lymphatic endothelial cells. Black arrows indicate intralymphatic fibrin and open arrows the endothelial cell bridging that followed.
(c) Intraluminal fibrin is more clearly demonstrated at higher magnification. L, lymphatic lumens. Bars: a and b, 5  m; c, 1  m. 
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VEGF-A may also have influenced the results in that the
amounts of vector injected to induce angiogenesis were
substantially higher than those used here (19).
The mechanisms by which VEGF-A induced the abnor-
mal lymphangiogenesis observed here have not yet been
worked out. Skobe and Detmar reported that VEGF-A
stimulates expression of VEGF-C in cultured vascular en-
dothelium (31). It was possible, therefore, that VEGF-A
induced lymphangiogenesis by up-regulating the expres-
sion of VEGF-C, a member of the VEGF family that has
been previously implicated in lymphangiogenesis (10, 14).
However, neither VEGF-C nor VEGF-D expression was
detected at any time by in situ hybridization in ears injected
with Ad-VEGF-A
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. Another possibility is that VEGF-A
acted directly to induce lymphatic endothelial cell prolifer-
ation through VEGFR-2. Although the literature is not
in perfect agreement (32), we have consistently found
VEGFR-2 to be expressed strongly on normal lymphatic
endothelium (23), and, as shown here, on giant lymphatics.
In further support of this possibility, VEGFR-2 is the re-
ceptor thought to mediate VEGF-A–induced proliferation
of blood vascular endothelium (8, 33). Finally, PlGF,
which induces angiogenesis but not lymphangiogenesis,
does not interact with VEGFR-2 (9). Other possibilities,
for example, that lymphangiogenesis results from a second-
ary effect of VEGF-A, such as prolonged interstitial edema,
must also be considered.
The giant lymphatics we have described here appear
identical to those found in lymphangiomas (34), suggesting
that VEGF-A may have a role in the genesis of lymphatic
tumors and malformations. To our knowledge, VEGF-A
expression has not been investigated in lymphangiomas,
though VEGF-C and VEGFR-2 and -3 are reportedly ex-
pressed (35, 36). Abnormally large lymphatics resembling
giant lymphatics are also a feature of Crohn’s disease (37,
38), a chronic inflammatory condition in which VEGF-A
is overexpressed (39, 40); therefore, VEGF-A may have a
role in the development of these abnormal lymphatics. Fi-
nally, there has been much debate about the existence of
lymphatics in various malignant tumors and the possible
role that lymphangiogenesis may play in tumor metastasis
(15, 16, 32). Some human and animal tumors do overex-
press VEGF-C and/or VEGF-D, and mouse tumor cells
engineered to overexpress either induce angiogenesis and
facilitate tumor metastasis (15, 32). It remains to be deter-
mined whether VEGF-A, a cytokine expressed by the vast
majority of malignant human tumors (5, 7), does likewise.
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